RT Journal Article
SR Electronic
T1 Long-term cardiac symptoms following COVID-19: a systematic review and meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.16.23284620
DO 10.1101/2023.01.16.23284620
A1 Boya Guo
A1 Chenya Zhao
A1 Mike Z. He
A1 Camilla Senter
A1 Zhenwei Zhou
A1 Jin Peng
A1 Song Li
A1 Annette L Fitzpatrick
A1 Sara Lindström
A1 Rebecca C Stebbins
A1 Grace A Noppert
A1 Chihua Li
YR 2023
UL http://medrxiv.org/content/early/2023/01/17/2023.01.16.23284620.abstract
AB Background There is growing body of literature on the long-term cardiac symptoms following COVID-19. We conducted a systematic review and meta-analysis to synthesize and evaluate related evidence to inform clinical management and future studies.Methods We searched two preprint and seven peer-reviewed article databases from January 1, 2020 to January 8, 2022 for studies investigating cardiac symptoms that persisted for at least 4 weeks among individuals who survived COVID-19. A customized Newcastle–Ottawa scale was used to evaluate the quality of included studies. Random-effects meta-analyses were performed to estimate the proportion of symptoms with 95% confidence intervals (CI), and stratified analyses were conducted to quantify the proportion of symptoms by study characteristics and quality.Results A total of 101 studies describing 49 unique long-term cardiac symptoms met the inclusion criteria. Based on quality assessment, only 15.8% of the studies (n=16) were of high quality, and most studies scored poorly on sampling representativeness. The two most examined symptoms were chest pain and arrhythmia. Meta-analysis showed that the proportion of chest pain was 10.1% (95% CI: 6.4-15.5) and arrhythmia was 9.8% (95% CI: 5.4-17.2). Stratified analyses showed that studies with low-quality score, small sample size, unsystematic sampling method, and cross-sectional design were most likely to report high proportions of symptoms. For example, the proportion of chest pain was 21.3% (95% CI: 10.5-38.5), 9.3% (95% CI: 6.0-14.0), and 4.0% (95% CI: 1.3-12.0) in studies with low, medium, and high-quality scores, respectively. Similar patterns were observed for other cardiac symptoms including hypertension, cardiac abnormalities, myocardial injury, thromboembolism, stroke, heart failure, coronary disease, and myocarditis.Discussion There is a wide spectrum of long-term cardiac symptoms following COVID-19. Findings of existing studies are strongly related to study quality, size and design, underscoring the need for high-quality epidemiologic studies to characterize these symptoms and understand their etiology.Evidence before this study Accumulating evidence shows long-term cardiac symptoms following COVID-19. However, no previous reviews systematically evaluated and synthesized findings from studies on long-term cardiac symptoms.Added value of this study This is the first systematic review and meta-analysis that focused on studies of long-term cardiac symptoms of COVID-19. We included 101 studies and identified 49 cardiac symptoms that are indicative of cardiac abnormalities. We scored their quality based on epidemiologic principles and identified domains of study design that need improvements. We quantified proportions of multiple long-term cardiac symptoms including chest pain, arrhythmia, and others. We also observed systematic differences in reported proportions of these symptoms by selected study characteristics, including total quality assessment score, sample size, sampling representativeness, and study design. High-quality studies identified here can provide important guidelines for future studies of long-term symptoms following COVID-19.Implications of all the available evidence Multiple domains of study design, especially sampling representativeness, need to be improved in future studies on long-term cardiac symptoms following COVID-19. Notably, low-quality and smaller studies tend to report a larger proportion of symptoms, are more likely to be subject to greater sampling variation, and hence are less precise. These studies should be revisited with the emergence of large studies with rigriours study designs. This systematic review and meta-analysis highlight the scope of persistent cardiac symptoms among those who survived the acute phase of COVID-19, and the importance of synthesizing rigorous evidence to inform post-COVID surveillance and management plans.Competing Interest StatementThe authors have declared no competing interest.Funding StatementChihua Li was supported by NIA R01AG070953 and R01AG075719; Grace A. Noppert was supported by NIA R00AG062749 and R01AG075719.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article or included as supplementary materials.